Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.05
LH's Cash-to-Debt is ranked lower than
95% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. LH: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
LH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: No Debt
Current: 0.05
Equity-to-Asset 0.39
LH's Equity-to-Asset is ranked lower than
78% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. LH: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
LH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.43 Max: 0.91
Current: 0.39
0.14
0.91
Debt-to-Equity 1.04
LH's Debt-to-Equity is ranked lower than
86% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. LH: 1.04 )
Ranked among companies with meaningful Debt-to-Equity only.
LH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05  Med: 0.89 Max: 4.96
Current: 1.04
0.05
4.96
Interest Coverage 6.02
LH's Interest Coverage is ranked lower than
75% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. LH: 6.02 )
Ranked among companies with meaningful Interest Coverage only.
LH' s Interest Coverage Range Over the Past 10 Years
Min: 3.63  Med: 10.84 Max: 14.88
Current: 6.02
3.63
14.88
Piotroski F-Score: 7
Altman Z-Score: 2.56
Beneish M-Score: -2.57
WACC vs ROIC
7.45%
7.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 13.38
LH's Operating Margin % is ranked higher than
78% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. LH: 13.38 )
Ranked among companies with meaningful Operating Margin % only.
LH' s Operating Margin % Range Over the Past 10 Years
Min: 11.48  Med: 17.58 Max: 19.94
Current: 13.38
11.48
19.94
Net Margin % 7.57
LH's Net Margin % is ranked higher than
73% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. LH: 7.57 )
Ranked among companies with meaningful Net Margin % only.
LH' s Net Margin % Range Over the Past 10 Years
Min: 5.04  Med: 10.08 Max: 11.72
Current: 7.57
5.04
11.72
ROE % 13.36
LH's ROE % is ranked higher than
76% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. LH: 13.36 )
Ranked among companies with meaningful ROE % only.
LH' s ROE % Range Over the Past 10 Years
Min: 11.27  Med: 22.19 Max: 28.64
Current: 13.36
11.27
28.64
ROA % 5.15
LH's ROA % is ranked higher than
71% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. LH: 5.15 )
Ranked among companies with meaningful ROA % only.
LH' s ROA % Range Over the Past 10 Years
Min: 4.09  Med: 8.75 Max: 11.43
Current: 5.15
4.09
11.43
ROC (Joel Greenblatt) % 51.26
LH's ROC (Joel Greenblatt) % is ranked higher than
82% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. LH: 51.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.26  Med: 104.98 Max: 138.05
Current: 51.26
51.26
138.05
3-Year Revenue Growth Rate 13.50
LH's 3-Year Revenue Growth Rate is ranked higher than
74% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. LH: 13.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.4  Med: 11.15 Max: 24.4
Current: 13.5
-21.4
24.4
3-Year EBITDA Growth Rate 8.90
LH's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. LH: 8.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.65 Max: 18
Current: 8.9
0
18
3-Year EPS without NRI Growth Rate 3.90
LH's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. LH: 3.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -30  Med: 15.1 Max: 82.8
Current: 3.9
-30
82.8
GuruFocus has detected 6 Warning Signs with Laboratory Corp of America Holdings $LH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LH's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

LH Guru Trades in Q3 2016

First Eagle Investment 226,794 sh (New)
Richard Pzena 2,185 sh (New)
John Hussman 25,000 sh (New)
Ray Dalio 30,844 sh (+58.07%)
David Dreman 2,683 sh (unchged)
First Pacific Advisors 20,400 sh (unchged)
Pioneer Investments 26,829 sh (unchged)
Wallace Weitz 766,205 sh (-4.87%)
John Rogers 1,438,798 sh (-5.03%)
Jeff Auxier 2,980 sh (-6.29%)
Keeley Asset Management Corp 43,106 sh (-8.63%)
Scott Black 17,477 sh (-10.48%)
Larry Robbins 4,212,026 sh (-22.81%)
Jim Simons 146,205 sh (-27.94%)
Joel Greenblatt 82,365 sh (-51.81%)
Mario Gabelli 5,400 sh (-68.97%)
Paul Tudor Jones 3,400 sh (-98.56%)
» More
Q4 2016

LH Guru Trades in Q4 2016

Charles Brandes 54,221 sh (New)
Richard Snow 16,700 sh (New)
Joel Greenblatt 149,653 sh (+81.69%)
First Eagle Investment 268,515 sh (+18.40%)
Richard Pzena 2,327 sh (+6.50%)
John Rogers 1,470,340 sh (+2.19%)
Wallace Weitz 778,751 sh (+1.64%)
Mario Gabelli 5,400 sh (unchged)
David Dreman 2,683 sh (unchged)
First Pacific Advisors 20,400 sh (unchged)
John Hussman Sold Out
Larry Robbins 4,188,260 sh (-0.56%)
Scott Black 17,076 sh (-2.29%)
Jeff Auxier 2,880 sh (-3.36%)
Keeley Asset Management Corp 40,406 sh (-6.26%)
Pioneer Investments 21,636 sh (-19.36%)
Paul Tudor Jones 1,800 sh (-47.06%)
Jim Simons 67,800 sh (-53.63%)
Ray Dalio 10,400 sh (-66.28%)
» More
Q1 2017

LH Guru Trades in Q1 2017

John Hussman 500 sh (New)
Steven Cohen 216,321 sh (New)
Jim Simons 184,305 sh (+171.84%)
Richard Snow 36,820 sh (+120.48%)
Charles Brandes 106,836 sh (+97.04%)
Paul Tudor Jones 2,300 sh (+27.78%)
Joel Greenblatt 169,432 sh (+13.22%)
David Dreman 2,683 sh (unchged)
First Eagle Investment Sold Out
Pioneer Investments Sold Out
Ray Dalio Sold Out
Scott Black 17,046 sh (-0.18%)
Richard Pzena 2,230 sh (-4.17%)
Wallace Weitz 740,019 sh (-4.97%)
John Rogers 1,396,357 sh (-5.03%)
First Pacific Advisors 16,560 sh (-18.82%)
Larry Robbins 2,664,988 sh (-36.37%)
Mario Gabelli 3,400 sh (-37.04%)
Jeff Auxier 1,800 sh (-37.50%)
» More
Q2 2017

LH Guru Trades in Q2 2017

Jim Simons 506,405 sh (+174.76%)
First Pacific Advisors 31,630 sh (+91.00%)
David Dreman 4,961 sh (+84.90%)
Steven Cohen 272,200 sh (+25.83%)
Wallace Weitz 764,090 sh (+3.25%)
John Hussman 500 sh (unchged)
Mario Gabelli 3,400 sh (unchged)
Richard Snow 36,820 sh (unchged)
Larry Robbins 2,664,988 sh (unchged)
Richard Pzena Sold Out
Paul Tudor Jones Sold Out
Charles Brandes 106,633 sh (-0.19%)
John Rogers 1,384,816 sh (-0.83%)
Jeff Auxier 1,775 sh (-1.39%)
Scott Black 16,684 sh (-2.12%)
Joel Greenblatt 127,626 sh (-24.67%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2017-06-30 Reduce -0.83%0.02%$137.51 - $152.97 $ 150.326%1,384,816
Wallace Weitz 2017-06-30 Add 3.25%0.16%$137.51 - $152.97 $ 150.326%764,090
Joel Greenblatt 2017-06-30 Reduce -24.67%0.08%$137.51 - $152.97 $ 150.326%127,626
Charles Brandes 2017-06-30 Reduce -0.19%$137.51 - $152.97 $ 150.326%106,633
David Dreman 2017-06-30 Add 84.90%0.19%$137.51 - $152.97 $ 150.326%4,961
Richard Pzena 2017-06-30 Sold Out $137.51 - $152.97 $ 150.326%0
John Rogers 2017-03-31 Reduce -5.03%0.11%$129.07 - $144.27 $ 150.329%1,396,357
Wallace Weitz 2017-03-31 Reduce -4.97%0.2%$129.07 - $144.27 $ 150.329%740,019
Joel Greenblatt 2017-03-31 Add 13.22%0.04%$129.07 - $144.27 $ 150.329%169,432
Charles Brandes 2017-03-31 Add 97.04%0.11%$129.07 - $144.27 $ 150.329%106,836
Mario Gabelli 2017-03-31 Reduce -37.04%$129.07 - $144.27 $ 150.329%3,400
Richard Pzena 2017-03-31 Reduce -4.17%$129.07 - $144.27 $ 150.329%2,230
First Eagle Investment 2017-03-31 Sold Out 0.09%$129.07 - $144.27 $ 150.329%0
John Rogers 2016-12-31 Add 2.19%0.05%$121.63 - $139.82 $ 150.3216%1,470,340
Wallace Weitz 2016-12-31 Add 1.64%0.07%$121.63 - $139.82 $ 150.3216%778,751
First Eagle Investment 2016-12-31 Add 18.40%0.01%$121.63 - $139.82 $ 150.3216%268,515
Joel Greenblatt 2016-12-31 Add 81.69%0.11%$121.63 - $139.82 $ 150.3216%149,653
Charles Brandes 2016-12-31 New Buy0.1%$121.63 - $139.82 $ 150.3216%54,221
Keeley Asset Management Corp 2016-12-31 Reduce -6.26%0.02%$121.63 - $139.82 $ 150.3216%40,406
Richard Pzena 2016-12-31 Add 6.50%$121.63 - $139.82 $ 150.3216%2,327
John Rogers 2016-09-30 Reduce -5.03%0.12%$130.73 - $140.98 $ 150.3210%1,438,798
Wallace Weitz 2016-09-30 Reduce -4.87%0.19%$130.73 - $140.98 $ 150.3210%766,205
First Eagle Investment 2016-09-30 New Buy0.08%$130.73 - $140.98 $ 150.3210%226,794
Joel Greenblatt 2016-09-30 Reduce -51.81%0.14%$130.73 - $140.98 $ 150.3210%82,365
Keeley Asset Management Corp 2016-09-30 Reduce -8.63%0.02%$130.73 - $140.98 $ 150.3210%43,106
Mario Gabelli 2016-09-30 Reduce -68.97%0.01%$130.73 - $140.98 $ 150.3210%5,400
Richard Pzena 2016-09-30 New Buy$130.73 - $140.98 $ 150.3210%2,185
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:DGX, NAS:IDXX, NYSE:Q, NYSE:A, NYSE:PKI, NYSE:BIO, NAS:DXCM, NAS:EXAS, NAS:INCR, NYSE:CRL, NAS:PRAH, NAS:BRKR, NAS:PRXL, NYSE:ALR, NAS:VWR, NAS:NEOG, NAS:MYGN, NAS:QDEL, NAS:FMI, NAS:AXDX » details
Traded in other countries:LAB.Germany,
Headquarter Location:USA
Laboratory Corp of America Holdings is a healthcare diagnostics company. It is engaged in providing comprehensive clinical laboratory and end-to-end drug development services.

Laboratory Corporation of America is the nation's second-largest independent clinical laboratory, with roughly 20% of the independent lab market. The company operates more than 1,800 patient-service centers, offering a broad range of clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing. With the addition of Covance, LabCorp also has a sizable footprint in the global contract research organization market.

Guru Investment Theses on Laboratory Corp of America Holdings

Weitz Funds Comments on Laboratory Corp. of America - May 18, 2017

Laboratory Corp. of America (LabCorp) (NYSE:LH) operates as a diversified global life sciences company through two segments: LabCorp Diagnostics and Covance Drug Development. Following a choppy 2016 third quarter, LabCorp’s fourth quarter operating results resumed a more normal course. Test volumes rebounded at LabCorp Diagnostics, as did new clinical trial bookings at Covance. The company closed the year on a high note, with sales increasing 11% and cash earnings per share up 12% versus the prior year. Underlying clinical lab trends remain stable and the pace of clinical research outsourcing continues to be healthy. Anticipated cuts in Medicare reimbursement for lab tests and a gradual shift by payers toward value-based payment models are creating new, long hoped-for opportunities for LabCorp’s low cost lab network. LabCorp announced the acquisition of two valuable hospital- based labs during the first quarter and continues to see a steady flow of attractive potential ‘tuck-in’ lab acquisition opportunities. The company’s combination of durable organic growth and significant reinvestment runway remains appealing to us as long-term investors



From Weitz Funds' first-quarter 2017 Balanced Fund shareholder letter.



Check out Wallace Weitz latest stock trades

Wally Weitz Comments on Laboratory Corp of America - Jul 20, 2016

Laboratory Corp. of America (NYSE:LH) is a healthcare diagnostics company providing comprehensive clinical laboratory services to medical professionals and end-to-end drug development support to pharmaceutical manufacturers. LabCorp reported stronger than expected organic growth during the first quarter in both its diagnostics and drug development segments and raised its financial forecast for the full year. Covance, its drug development segment, has demonstrated improving operating momentum the past three quarters, with strength across each of its primary end markets (pre-clinical, central lab, late stage). Finally, the Center for Medicare and Medicaid Services’ (CMS’) highly anticipated Final Rule on changes to the Medicare Clinical Lab Fee Schedule in mid-June included two positives for the lab industry – a delay in implementation until 2018 and the inclusion of higher cost outpatient hospital labs, which is a piece that will determine future reimbursement levels. While final details won’t be known for some time, we anticipate these reimbursement changes will have a very modest impact on LabCorp’s future earnings power.



From Weitz Partners Fund's second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Laboratory Corp. of America Holdings - Apr 25, 2016

Laboratory Corp. of America Holdings (NYSE:LH) is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to -end drug development support. The company’s strong competitive position, durable excess cash flow and exemplary management have been mainstays of the Laboratory Corp. investment thesis over many years. Various Weitz managed portfolios have been investors in the company over the past 10+ years. We initiated the position, as both the diagnostic lab and drug development market continued to experience healthy demand. A little over one year in, LabCorp’s $6 billion acquisition of Covance appears to be bearing early fruit in the form of new customer wins and central lab market share gains. With revenue and cost synergies on track, financial leverage returning to target levels and stable reimbursement, we believe this stock can compound wealth for years to come.



From Weitz Funds' Research Fund commentary 1st quarter.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Laboratory Corporation of America Holdings - Feb 01, 2016

Laboratory Corporation of America Holdings (NYSE:LH) offers testing services used by medical professionals in core testing, patient diagnosis and the monitoring and treatment of disease. LabCorp shares rose during the fourth quarter, rebounding after a poor month in September. The company’s most recent financial results showed continued strength in the legacy Diagnostics segment with +5% organic sales growth versus the prior year and a healthy increase in profitability. Results in the still relatively new Covance Drug Development business improved, consistent with management’s expectations earlier in the year. Following a 3-year period of relatively stagnant growth, LabCorp appears poised for a return to healthy, double-digit per share earnings growth over the next several years as the company leverages the commercial strength of its combined operations.



From Weitz Funds' Balanced Fund fourth quarter 2015 commentary.



Check out Wallace Weitz latest stock trades

Top Ranked Articles about Laboratory Corp of America Holdings

Wally Weitz to Join GuruFocus for Podcast Ask a question for the 'Other Oracle of Omaha'
As a renowned investor and resident of Warren Buffett (Trades, Portfolio)’s hometown, Weitz is often dubbed the "Other Oracle of Omaha.” Read more...
The National Football League Alumni Association, Cancer Treatment Centers of America® and LabCorp Team Up to Offer Prostate Cancer Screenings Starting in September
Interpace Diagnostics Announces Renewal and Extension of LabCorp National Agreement
ChromaDex Sells its Analytical Testing Business to LabCorp, to Accelerate the Expansion of Nicotinamide Riboside and its Other Patented Ingredient Technologies
OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
The Tortoise Is in the Logo for a Reason John Rogers invokes the fable of the tortoise and the hare to make the case for his patient approach to value investing
Coalition for Access to Prenatal Screening Announces Clinical Advisory Board
Weitz Funds Comments on Laboratory Corp. of America Guru stock highlight
Laboratory Corp. of America (LabCorp) (NYSE:LH) operates as a diversified global life sciences company through two segments: LabCorp Diagnostics and Covance Drug Development. Following a choppy 2016 third quarter, LabCorp’s fourth quarter operating results resumed a more normal course. Test volumes rebounded at LabCorp Diagnostics, as did new clinical trial bookings at Covance. The company closed the year on a high note, with sales increasing 11% and cash earnings per share up 12% versus the prior year. Underlying clinical lab trends remain stable and the pace of clinical research outsourcing continues to be healthy. Anticipated cuts in Medicare reimbursement for lab tests and a gradual shift by payers toward value-based payment models are creating new, long hoped-for opportunities for LabCorp’s low cost lab network. LabCorp announced the acquisition of two valuable hospital- based labs during the first quarter and continues to see a steady flow of attractive potential ‘tuck-in’ lab acquisition opportunities. The company’s combination of durable organic growth and significant reinvestment runway remains appealing to us as long-term investors Read more...
LabCorp Stock Flat; Class-Action Lawsuit Filed for Overcharging Patients without insurance charged more for diagnostic tests, litigation claims
Laboratory Corp. of America Holdings (NYSE:LH) stock is under pressure, as the company's stock fell 0.25% in midday trading on Tuesday. The drop comes after an announcement that the company, known as LabCorp, is being sued in a class-action lawsuit. The lawsuit, filed last week, alleges that the company has been overcharging customers for diagnostic tests. Read more...
5 Companies Reach Yearly Highs Multiple companies have achieved 52-week milestones
According to GuruFocus list of 52-week highs, these stocks have reached their 52-Week Highs. Read more...

Ratios

vs
industry
vs
history
PE Ratio 21.23
LH's PE Ratio is ranked higher than
75% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. LH: 21.23 )
Ranked among companies with meaningful PE Ratio only.
LH' s PE Ratio Range Over the Past 10 Years
Min: 13  Med: 17.25 Max: 29.28
Current: 21.23
13
29.28
Forward PE Ratio 15.04
LH's Forward PE Ratio is ranked higher than
97% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. LH: 15.04 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.23
LH's PE Ratio without NRI is ranked higher than
75% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. LH: 21.23 )
Ranked among companies with meaningful PE Ratio without NRI only.
LH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13  Med: 17.25 Max: 29.28
Current: 21.23
13
29.28
Price-to-Owner-Earnings 17.40
LH's Price-to-Owner-Earnings is ranked higher than
79% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. LH: 17.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.35  Med: 14.3 Max: 42.34
Current: 17.4
9.35
42.34
PB Ratio 2.64
LH's PB Ratio is ranked higher than
66% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. LH: 2.64 )
Ranked among companies with meaningful PB Ratio only.
LH' s PB Ratio Range Over the Past 10 Years
Min: 2.11  Med: 3.39 Max: 5.19
Current: 2.64
2.11
5.19
PS Ratio 1.58
LH's PS Ratio is ranked higher than
82% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. LH: 1.58 )
Ranked among companies with meaningful PS Ratio only.
LH' s PS Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.61 Max: 2.97
Current: 1.58
1.2
2.97
Price-to-Free-Cash-Flow 16.49
LH's Price-to-Free-Cash-Flow is ranked higher than
74% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. LH: 16.49 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.14  Med: 14.58 Max: 32.39
Current: 16.49
9.14
32.39
Price-to-Operating-Cash-Flow 12.74
LH's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. LH: 12.74 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.46  Med: 11.3 Max: 21.23
Current: 12.74
7.46
21.23
EV-to-EBIT 16.07
LH's EV-to-EBIT is ranked higher than
77% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LH: 16.07 )
Ranked among companies with meaningful EV-to-EBIT only.
LH' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 11.7 Max: 21.6
Current: 16.07
8.7
21.6
EV-to-EBITDA 11.61
LH's EV-to-EBITDA is ranked higher than
79% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. LH: 11.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
LH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 9.6 Max: 16.2
Current: 11.61
7.2
16.2
EV-to-Revenue 2.14
LH's EV-to-Revenue is ranked higher than
75% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. LH: 2.14 )
Ranked among companies with meaningful EV-to-Revenue only.
LH' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 2 Max: 3.1
Current: 2.14
1.6
3.1
PEG Ratio 3.10
LH's PEG Ratio is ranked higher than
52% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.20 vs. LH: 3.10 )
Ranked among companies with meaningful PEG Ratio only.
LH' s PEG Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.61 Max: 6.3
Current: 3.1
0.84
6.3
Shiller PE Ratio 25.86
LH's Shiller PE Ratio is ranked higher than
77% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. LH: 25.86 )
Ranked among companies with meaningful Shiller PE Ratio only.
LH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.84  Med: 23.87 Max: 61.83
Current: 25.86
18.84
61.83
Current Ratio 1.39
LH's Current Ratio is ranked lower than
77% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. LH: 1.39 )
Ranked among companies with meaningful Current Ratio only.
LH' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.63 Max: 4.38
Current: 1.39
0.47
4.38
Quick Ratio 1.28
LH's Quick Ratio is ranked lower than
74% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. LH: 1.28 )
Ranked among companies with meaningful Quick Ratio only.
LH' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.53 Max: 4.38
Current: 1.28
0.44
4.38
Days Inventory 11.11
LH's Days Inventory is ranked higher than
89% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. LH: 11.11 )
Ranked among companies with meaningful Days Inventory only.
LH' s Days Inventory Range Over the Past 10 Years
Min: 10.44  Med: 12.14 Max: 13.23
Current: 11.11
10.44
13.23
Days Sales Outstanding 51.20
LH's Days Sales Outstanding is ranked higher than
65% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. LH: 51.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
LH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.64  Med: 49.42 Max: 55.91
Current: 51.2
44.64
55.91
Days Payable 27.23
LH's Days Payable is ranked lower than
79% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. LH: 27.23 )
Ranked among companies with meaningful Days Payable only.
LH' s Days Payable Range Over the Past 10 Years
Min: 20.61  Med: 27.89 Max: 32.38
Current: 27.23
20.61
32.38

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.60
LH's 5-Year Yield-on-Cost % is ranked lower than
76% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. LH: 0.60 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
LH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.6
3-Year Average Share Buyback Ratio -6.20
LH's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. LH: -6.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -42.1  Med: 1.95 Max: 6.6
Current: -6.2
-42.1
6.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.09
LH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
87% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. LH: 1.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.56  Med: 1.08 Max: 4.87
Current: 1.09
0.56
4.87
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.91
LH's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
61% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. LH: 1.91 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
LH' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.75  Med: 1.03 Max: 2.47
Current: 1.91
0.75
2.47
Price-to-Median-PS-Value 0.99
LH's Price-to-Median-PS-Value is ranked higher than
52% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. LH: 0.99 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 1.02 Max: 2.98
Current: 0.99
0.07
2.98
Price-to-Peter-Lynch-Fair-Value 3.10
LH's Price-to-Peter-Lynch-Fair-Value is ranked lower than
67% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. LH: 3.10 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LH' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.64 Max: 5.48
Current: 3.1
0.63
5.48
Earnings Yield (Greenblatt) % 6.23
LH's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. LH: 6.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.6  Med: 8.5 Max: 11.4
Current: 6.23
4.6
11.4
Forward Rate of Return (Yacktman) % 11.40
LH's Forward Rate of Return (Yacktman) % is ranked higher than
58% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. LH: 11.40 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 10  Med: 16.9 Max: 23.2
Current: 11.4
10
23.2

More Statistics

Revenue (TTM) (Mil) $9,833.00
EPS (TTM) $ 7.14
Beta1.20
Short Percentage of Float2.09%
52-Week Range $119.51 - 164.22
Shares Outstanding (Mil)101.80

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 10,012 10,590 11,057 11,956
EPS ($) 9.50 10.37 11.16 12.75
EPS without NRI ($) 9.50 10.37 11.16 12.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.54%
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}